These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 18794660)

  • 41. Potential lower efficacy of molindone among first-generation antipsychotics.
    Waugaman RM
    Am J Psychiatry; 2009 Apr; 166(4):491; author reply 492-3. PubMed ID: 19339370
    [No Abstract]   [Full Text] [Related]  

  • 42. An evaluation of monitoring practices in patients on second generation antipsychotics.
    Nguyen D; Brakoulias V; Boyce P
    Australas Psychiatry; 2009 Aug; 17(4):295-9. PubMed ID: 19585292
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Body weight gain after administration of antipsychotic drugs.
    Baptista T; Lacruz A; De Mendoza D; Mendoza JM; Silvera R; Angeles F; Mendoza MT; Hernandez L
    Pharmacopsychiatry; 2002 Jan; 35(1):36. PubMed ID: 11819161
    [No Abstract]   [Full Text] [Related]  

  • 44. Almost all antipsychotics result in weight gain: a meta-analysis.
    Bak M; Fransen A; Janssen J; van Os J; Drukker M
    PLoS One; 2014; 9(4):e94112. PubMed ID: 24763306
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A prospective study of adverse effects of antipsychotics in adolescents with schizophrenia during a 6-month follow-up.
    Ulloa RE; Pérez-Garza R; Arce S; Bermúdez Y; Palacios L
    Int Clin Psychopharmacol; 2019 Jan; 34(1):33-36. PubMed ID: 29958237
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Use and safety of antipsychotic drugs during pregnancy.
    Einarson A; Boskovic R
    J Psychiatr Pract; 2009 May; 15(3):183-92. PubMed ID: 19461391
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Introduction: weighing the evidence: weight management insights for treating major mental illness.
    Citrome L
    J Clin Psychiatry; 2007; 68 Suppl 12():4. PubMed ID: 17956149
    [No Abstract]   [Full Text] [Related]  

  • 48. Polymorphisms of the LEP- and LEPR gene and obesity in patients using antipsychotic medication.
    Gregoor JG; van der Weide J; Mulder H; Cohen D; van Megen HJ; Egberts AC; Heerdink ER
    J Clin Psychopharmacol; 2009 Feb; 29(1):21-5. PubMed ID: 19142102
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Acetazolamide for Antipsychotic-Associated Weight Gain in Schizophrenia.
    Kakunje A; Prabhu A; Priya Es S; Karkal R; Pookoth RK; Pd R
    J Clin Psychopharmacol; 2018 Dec; 38(6):652-653. PubMed ID: 30192255
    [No Abstract]   [Full Text] [Related]  

  • 50. Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents.
    McIntyre RS; Jerrell JM
    Arch Pediatr Adolesc Med; 2008 Oct; 162(10):929-35. PubMed ID: 18838645
    [TBL] [Abstract][Full Text] [Related]  

  • 51. One ace and three faults don't win the set.
    George D; Reilly JG; Kwentoh ML
    Br J Psychiatry; 2009 Jan; 194(1):88-9; author reply 89. PubMed ID: 19118335
    [No Abstract]   [Full Text] [Related]  

  • 52. Association Between Weight Gain and Remission Status at 3 Months in First-Episode Schizophrenia.
    Oh N; See YM; Remington G; Lee J
    J Clin Psychopharmacol; 2016 Aug; 36(4):403-5. PubMed ID: 27187561
    [No Abstract]   [Full Text] [Related]  

  • 53. Psychofarmacology in the prevention of somatic comorbid diseases in mentally ill patients.
    Jukić V; Petrović Z; Brecić P; Krizaj A; Savić A; Baceković A; Bilić P; Susac J; Mandić A; Prazen I
    Psychiatr Danub; 2009 Sep; 21(3):350-5. PubMed ID: 19794355
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Body mass index changes and chronic neuroleptic drug treatment for Tourette syndrome.
    Degrauw RS; Li JZ; Gilbert DL
    Pediatr Neurol; 2009 Sep; 41(3):183-6. PubMed ID: 19664533
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pregnancy and atypical antipsychotics.
    Ruzić K; Dadić-Hero E; Knez R; Medved P; Petrić D
    Psychiatr Danub; 2009 Sep; 21(3):368-70. PubMed ID: 19794358
    [TBL] [Abstract][Full Text] [Related]  

  • 56. No association of serotonin transporter polymorphism (5-HTTVNTR and 5-HTTLPR) with characteristics and treatment response to atypical antipsychotic agents in schizophrenic patients.
    Lee HY; Kim DJ; Lee HJ; Choi JE; Kim YK
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):276-80. PubMed ID: 19059448
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of medical comorbidity on medication management of schizophrenia.
    Haupt DW
    CNS Spectr; 2007 Dec; 12(12 Suppl 21):15-7. PubMed ID: 18389928
    [No Abstract]   [Full Text] [Related]  

  • 58. Effects of six second generation antipsychotics on body weight and metabolism - risk assessment and results from a prospective study.
    Tschoner A; Engl J; Rettenbacher M; Edlinger M; Kaser S; Tatarczyk T; Effenberger M; Patsch JR; Fleischhacker WW; Ebenbichler CF
    Pharmacopsychiatry; 2009 Jan; 42(1):29-34. PubMed ID: 19153944
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nonsignificant weight gain with atypical antipsychotics in men with Alzheimer's Disease: an important result of the CATIE-Alzheimer's disease study.
    Bagepally BS; Prakash O
    Am J Psychiatry; 2009 Sep; 166(9):1063-4; author reply 1064-5. PubMed ID: 19723796
    [No Abstract]   [Full Text] [Related]  

  • 60. Comparison of patient and clinician perspectives in the assessment of antipsychotic medication adherence.
    Barbui C; Kikkert M; Mazzi MA; Becker T; Bindman J; Schene A; Nosè M; Helm H; Thornicroft G; Tansella M
    Psychopathology; 2009; 42(5):311-7. PubMed ID: 19672133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.